An announcement from SciSparc Ltd. ( (SPRC) ) is now available.
On March 10, 2025, SciSparc Ltd. announced a significant development in its collaboration with Clearmind Medicine Inc., leading to the publication of a patent application in South Korea for a treatment targeting cocaine addiction. This patent application, based on preclinical trials, highlights the potential of a combination treatment using Clearmind’s MEAI and SciSparc’s PEA. The trials demonstrated a reduction in cocaine-induced cravings without affecting natural reward responses, suggesting a targeted approach to drug-related compulsions. This development is part of the ongoing efforts by SciSparc and Clearmind to expand their intellectual property portfolio globally, potentially impacting the treatment landscape for addiction.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders using cannabinoid pharmaceuticals. The company is engaged in drug development programs for conditions such as Tourette Syndrome, Alzheimer’s disease, pain, and ASD. It also has a subsidiary selling hemp seed oil-based products.
YTD Price Performance: 2.56%
Average Trading Volume: 10,890,224
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.33M
For a thorough assessment of SPRC stock, go to TipRanks’ Stock Analysis page.